09:01:22 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-15 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-08 Kvartalsrapport 2024-Q1
2024-04-17 Ordinarie utdelning BAVA 0.00 DKK
2024-04-16 Årsstämma 2024
2024-03-06 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-09 Kvartalsrapport 2023-Q1
2023-03-31 Ordinarie utdelning BAVA 0.00 DKK
2023-03-30 Årsstämma 2023
2023-03-02 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-09 Kvartalsrapport 2022-Q1
2022-04-06 Ordinarie utdelning BAVA 0.00 DKK
2022-04-05 Årsstämma 2022
2022-03-04 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-21 Ordinarie utdelning BAVA 0.00 DKK
2021-04-20 Årsstämma 2021
2021-03-12 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-15 Ordinarie utdelning BAVA 0.00 DKK
2020-06-12 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-27 Extra Bolagsstämma 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-25 Ordinarie utdelning BAVA 0.00 DKK
2019-04-24 Årsstämma 2019
2018-04-18 Ordinarie utdelning BAVA 0.00 DKK
2018-04-17 Årsstämma 2018
2017-04-26 Ordinarie utdelning BAVA 0.00 DKK
2017-04-25 Årsstämma 2017
2016-04-21 Ordinarie utdelning BAVA 0.00 DKK
2016-04-20 Årsstämma 2016
2015-04-24 Ordinarie utdelning BAVA 0.00 DKK
2015-04-23 Årsstämma 2015
2014-04-25 Ordinarie utdelning BAVA 0.00 DKK
2014-04-24 Årsstämma 2014
2013-04-18 Ordinarie utdelning BAVA 0.00 DKK
2013-04-17 Årsstämma 2013
2012-04-17 Ordinarie utdelning BAVA 0.00 DKK
2012-04-16 Årsstämma 2012
2011-04-27 Ordinarie utdelning BAVA 0.00 DKK
2011-04-26 Årsstämma 2011
2010-04-28 Ordinarie utdelning BAVA 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Bavarian Nordic är verksamma inom biokemi. Idag är bolaget specialiserade inom utveckling, produktion och distribution av vaccin mot infektionssjukdomar i samband med cancerbehandling. Utöver huvudverksamheten framställs även vacciner mot allvarliga sjukdomar som ebola och livmoderhalscancer. Störst verksamhet återfinns inom Europa och Nordamerika, med huvudkontoret beläget i Kvistgaard, Danmark.
2024-04-16 18:20:32

COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:

  • The Annual Report for 2023 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2024 was also adopted.
  • The Remuneration Report for 2023 was approved.
  • The Board of Directors and the Board of Management were discharged from liability.
  • Luc Debryune, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter and Johan van Hoof were re-elected, and Montse Montaner was elected to the Board of Directors. The Board of Directors constituted itself with Luc Debruyne as Chairman and Anders Gersel Pedersen as Deputy Chairman.
  • KPMG was elected as the Company’s new auditor.
  • The proposal to authorize the Board of Directors to increase the share capital of the Company was adopted.
  • The proposal to authorize the Board of Directors to issue convertible notes which give the right to subscribe for new shares in the Company was adopted.
  • The proposal to authorize the Board of Directors to issue warrants was adopted.
  • The Remuneration Policy was approved.
  • The proposed remuneration of the Board of Directors and the Board Committees for the current financial year was approved.
  • The proposal to authorize the Board of Directors on behalf of the Company to purchase own shares in the Company was adopted.

Minutes and voting results from the Annual General Meeting will be published on the Company’s website within two weeks.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 07 / 2024